NeoGraph Analytics
Medical ImagingGlobal2024 – 2032

AI in Cancer Diagnostics Market Size, Share and Trends Analysis

Published estimates for the AI in cancer diagnostics market range from $1.7B to $17.9B by 2032, a 7x spread driven by scope rather than growth.

Revenue, 2024

$1.0B

Forecast, 2032

$2.4B

CAGR, 2025-2032

11.16%

Report Coverage

Global

Code: ai-in-cancer-diagnostics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published forecasts for AI in cancer diagnostics disagree by a factor of seven. For 2032, estimates run from roughly $1.7 billion to $17.9 billion. That spread is not a disagreement about how fast the technology will be adopted. It is a disagreement about what is being counted.

Narrow definitions, covering software whose cleared indication is the detection or characterisation of cancer, cluster tightly. DelveInsight puts the market at $1.05 billion in 2024 reaching $2.43 billion by 2032 (11.16% CAGR), SNS Insider at $0.96 billion in 2023 reaching $2.46 billion by 2032 (11.0%), and Precedence Research at $0.89 billion in 2022 reaching $2.08 billion by 2032 (9.35%). Three independent houses landing within 15% of each other on the 2032 endpoint is a meaningful signal. Broader definitions diverge sharply: Global Market Insights reports $17.9 billion by 2032 at 29.2% CAGR, but for all of AI in oncology, with treatment planning, trial matching and clinical workflow included rather than diagnostics alone.

This report adopts the narrow definition and uses DelveInsight's endpoints as its spine, because that definition is the one that can be checked against something countable: regulatory authorisations. The FDA's AI-enabled device list is public. It records 1,524 authorised devices through Q1 2026, of which 1,164, or 76%, are radiology. Annual authorisations have risen from 221 in 2023 to 253 in 2024 to roughly 295 in 2025, with 92 in Q1 2026 alone. That is unit growth in the high teens against low-double-digit revenue growth in the narrow forecasts, which implies falling average revenue per cleared device. The reading is a market where clearance is becoming a commodity and differentiation is moving elsewhere.

The structural conclusion follows from the 76%. AI in cancer diagnostics is, in practice, largely imaging. Computational pathology is where the regulatory firsts have happened, with Paige holding a De Novo authorisation for AI-assisted prostate cancer detection and PathAI receiving 510(k) clearance for AISight Dx in June 2025, but imaging remains the volume. Consolidation has begun: Tempus acquired Paige in August 2025 for $81.25 million, largely in stock, a modest figure for the holder of the category's landmark authorisation.

02

Key Highlights

1

Published 2032 estimates span $1.7B to $17.9B, a 7x range driven by scope definition rather than disagreement over growth

2

Three independent houses (DelveInsight, SNS Insider, Precedence) land within 15% of each other on a narrow definition, clustering at $2.0-2.5B by 2032

3

The FDA has authorised 1,524 AI-enabled devices through Q1 2026; 1,164 (76%) are radiology, so this market is in practice largely imaging

4

Authorisations grew from 221 (2023) to 253 (2024) to about 295 (2025), unit growth in the high teens against low-double-digit revenue growth

5

That gap implies falling revenue per cleared device: regulatory access is commoditising faster than the market is growing

6

Tempus acquired Paige for $81.25M in August 2025, a modest price for the holder of the category's De Novo authorisation

7

The absence of a durable reimbursement pathway is the main reason conservative estimates have held

03

Market Overview

Market Context

Cancer diagnosis is a pattern-recognition problem performed under a workforce constraint. Radiology and pathology both face rising case volumes against a roughly flat supply of specialists. That is the condition under which assistive software gets adopted, regardless of whether it is strictly better than a human reader. The constraint also explains why authorisations cluster so heavily in radiology. Imaging produces standardised digital output at scale, which is what supervised learning requires. Pathology has had to digitise first, since whole-slide imaging is a precondition rather than a feature, which is why its regulatory milestones arrived later and remain fewer. The commercial question is therefore not whether these tools work. It is who captures the value once clearance is no longer scarce.

The AI in cancer diagnostics market is estimated at $1.05 billion in 2024, projected to reach $2.43 billion by 2032 at an 11.16% CAGR on a narrow definition covering software cleared for cancer detection and characterisation. Broader definitions that include treatment planning and workflow reach $17.9 billion over the same period.

Market Stage

Early growth, with regulatory access commoditising faster than revenue

Adoption Level

Established in imaging workflows; earlier in digital pathology

Key Trends

Published estimates differ by up to 7x on scope definition rather than growth assumptionsRadiology accounts for 76% of all FDA AI-enabled device authorisations (1,164 of 1,524)Annual FDA authorisations rose from 221 (2023) to 253 (2024) to about 295 (2025), with 92 in Q1 2026Unit growth outpacing revenue growth implies falling revenue per cleared deviceConsolidation underway: Tempus acquired Paige for $81.25M in August 2025Computational pathology holds the regulatory firsts; imaging holds the volume
04

Market Forecast & Data

Market Growth Forecast
2025-2032 · CAGR 11.16%

Base Year (2024)

$1.0B

Forecast (2032)

$2.4B

CAGR (2025-2032)

11.16%

Market size by year, 2025-2032, in USD Billion.
YearMarket size ($ Billion)
2024Base year$1.05B
2025$1.17B
2026$1.30B
2027$1.44B
2028$1.60B
2029$1.78B
2030$1.98B
2031$2.20B
2032$2.43B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR. How these figures are produced.
Forecast Analysis

The curve shown here is modelled at a constant 11.16% CAGR between DelveInsight's published 2024 and 2032 endpoints. It is deliberately not presented as a year-by-year prediction. No published source discloses annual figures for this market, and inventing inflection points would imply knowledge that does not exist. What can be said about the shape comes from the authorisation data. Device clearances grew roughly 14% from 2023 to 2024 and 17% from 2024 to 2025, and Q1 2026 alone added 92. If unit growth continues to outpace revenue growth, the implication is price compression rather than a demand inflection: more cleared products competing for a market growing more slowly than the supply of them. The principal risk to the low estimates is reimbursement. Diagnostic AI has largely been sold into capital or operating budgets rather than billed per use. A durable reimbursement pathway would break the narrow forecasts upward and move the market toward the broader definitions. Its absence is the single largest reason the conservative estimates have held.

05

Market Dynamics

  • Rising case volumes against a flat supply of radiologists and pathologists
  • Standardised digital imaging output, the precondition supervised learning requires
  • A widening base of cleared products lowering the barrier to procurement
  • Whole-slide imaging adoption opening pathology to computational tools
06

Market Segmentation

By Modality
Market share distribution across 2 segments
By Modality — market share by segment, in percent.
SegmentShare
Radiology and medical imaging1,164 of 1,524 FDA-authorised AI-enabled devices through Q1 2026. The volume of the market, and the reason AI in cancer diagnostics is in practice largely imaging.76.0%
All other specialties combinedIncludes computational pathology, cardiology, neurology and others. Pathology holds the category's landmark authorisations despite smaller unit counts.24.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
07

Competitive Landscape

T

Tempus AI

United States

Consolidator

Acquired Paige in August 2025 for $81.25 million, largely in stock, taking ownership of the category's De Novo prostate authorisation. Launched Paige Predict, covering predictions across 123 molecular biomarkers in 16 cancer types.

P

Paige

United States

Regulatory pioneer, now part of Tempus

Holder of the landmark De Novo authorisation for AI-assisted prostate cancer detection in pathology, plus Breakthrough Device Designations for Paige Breast Lymph Node and Paige PanCancer Detect.

P

PathAI

United States

Computational pathology challenger

Received FDA 510(k) clearance for AISight Dx in June 2025, extending digital pathology tooling toward clinical diagnostic use.

08

Recent Developments

26
2026US FDA

AI-enabled device list reaches 1,524 authorisations, 1,164 of them radiology, after 92 new authorisations in Q1 2026.

25
2025Tempus AI

Acquired Paige for $81.25 million, largely in stock, consolidating the holder of the category's landmark pathology authorisation.

25
2025PathAI

Received FDA 510(k) clearance for AISight Dx in June 2025.

25
2025US FDA

Approximately 295 AI-enabled device clearances from 221 manufacturers, up from 253 in 2024 and 221 in 2023.

09

Regulatory Landscape

FDA AI-Enabled Medical Device List, the public register underlying this report's unit countsFDA 510(k) pathway, the route for most AI diagnostic clearancesFDA De Novo pathway, used for first-of-kind tools such as AI-assisted prostate pathologyFDA Breakthrough Device Designation, held by Paige Breast Lymph Node and Paige PanCancer DetectEU In Vitro Diagnostic Regulation (IVDR), governing equivalent tools in the European market
10

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. This report is a synthesis of public sources and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • FDA AI-Enabled Medical Device List: counts through Q1 2026 (1,524 total, 1,164 radiology, 92 authorised in Q1 2026)
  • Published market estimates from DelveInsight (2025), SNS Insider (January 2025), Precedence Research, Allied Market Research and Global Market Insights
  • Company announcements and trade reporting on the Tempus-Paige transaction (August 2025) and the PathAI AISight Dx clearance (June 2025)

Validation: Market size is taken from DelveInsight's published 2024 and 2032 endpoints; intermediate years are modelled at a constant 11.16% CAGR and are presented as a modelled curve rather than observed annual data. Where published estimates diverge, the range is reported rather than averaged, and the cause of divergence is stated. Segmentation uses the FDA specialty split because it is countable. No regional or country breakdown is published for this market at a defensible level of confidence, so those sections are omitted rather than estimated. The FDA notes that its list is not a comprehensive resource of AI-enabled medical devices, so unit counts are a floor.

11

Strategic Takeaways

Investors

treat any single headline figure for this market as unusable without its scope definition, since the 7x spread is definitional. Reimbursement policy, not model accuracy, is the variable that would re-rate the sector.

Diagnostic vendors

FDA clearance is no longer a differentiator at roughly 295 authorisations a year. Defensibility is shifting to distribution, integration with incumbent PACS and LIS estates, and evidence that supports a billable claim.

Health systems

the 76% radiology concentration means imaging AI procurement is a mature buy with many substitutes, while pathology AI remains a thinner market gated on whole-slide imaging capital spend.

Strategy teams

the Tempus-Paige price of $81.25M against the category's landmark authorisation is the clearest available signal of how this market prices regulatory position versus distribution.

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.